CN101573110A - 降低葡萄糖水平的方法 - Google Patents

降低葡萄糖水平的方法 Download PDF

Info

Publication number
CN101573110A
CN101573110A CNA2007800400375A CN200780040037A CN101573110A CN 101573110 A CN101573110 A CN 101573110A CN A2007800400375 A CNA2007800400375 A CN A2007800400375A CN 200780040037 A CN200780040037 A CN 200780040037A CN 101573110 A CN101573110 A CN 101573110A
Authority
CN
China
Prior art keywords
ramipril
patient
disease
glucose
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800400375A
Other languages
English (en)
Chinese (zh)
Inventor
H·格斯坦
S·优素福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN101573110A publication Critical patent/CN101573110A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
CNA2007800400375A 2006-08-28 2007-08-14 降低葡萄糖水平的方法 Pending CN101573110A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84085006P 2006-08-28 2006-08-28
US60/840,850 2006-08-28

Publications (1)

Publication Number Publication Date
CN101573110A true CN101573110A (zh) 2009-11-04

Family

ID=38578487

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800400375A Pending CN101573110A (zh) 2006-08-28 2007-08-14 降低葡萄糖水平的方法

Country Status (12)

Country Link
US (1) US20080188538A1 (https=)
EP (1) EP2059242A1 (https=)
JP (1) JP2010501604A (https=)
KR (1) KR20090042976A (https=)
CN (1) CN101573110A (https=)
AU (1) AU2007291602B2 (https=)
BR (1) BRPI0716411A2 (https=)
CA (1) CA2661598A1 (https=)
IL (1) IL197189A0 (https=)
MX (1) MX2009002091A (https=)
NO (1) NO20090926L (https=)
WO (1) WO2008025450A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
IL161388A0 (en) * 2001-10-17 2004-09-27 Aventis Pharma Gmbh Method of reducing type 2 diabetes in high risk patients
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
WO2004080482A2 (en) * 2003-03-11 2004-09-23 Institut De Cardiologie De Montréal / Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure

Also Published As

Publication number Publication date
EP2059242A1 (en) 2009-05-20
AU2007291602A1 (en) 2008-03-06
BRPI0716411A2 (pt) 2013-09-24
AU2007291602B2 (en) 2012-09-06
NO20090926L (no) 2009-03-27
KR20090042976A (ko) 2009-05-04
JP2010501604A (ja) 2010-01-21
MX2009002091A (es) 2009-03-09
WO2008025450A1 (en) 2008-03-06
US20080188538A1 (en) 2008-08-07
IL197189A0 (en) 2009-12-24
CA2661598A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
US11648206B2 (en) Sustained-release formulations of colchicine and methods of using same
TW200401631A (en) Pharmaceutical composition for treating diabetes or a disease or condition associated with diabetes
KR20070085754A (ko) 안정화된 라미프릴 조성물 및 제조 방법
CN108012527A (zh) 苯并咪唑衍生物用于夜间酸突破的用途
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
TW200843741A (en) Pharmaceutical composition
KR100709528B1 (ko) 혈당콘트롤용 의약조성물
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
US20210361582A1 (en) Colchicine salicylate derivatives and methods of treatment
TWI867128B (zh) 前列腺環素衍生物用於製造用以抑制轉入透析或腎死之藥劑之用途
CN105663152A (zh) 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN101573110A (zh) 降低葡萄糖水平的方法
HK1138182A (en) Methods of lowering glucose levels
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
JP2006076956A (ja) 胃炎の治療・予防用配合剤
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
JPWO2006115115A1 (ja) ２型糖尿病治療用の併用医薬
WO2025108313A1 (zh) 包含egfr抑制剂的药物组合物
JPH11246438A (ja) 新規な抗アレルギー抗炎症組成物
HK1080411A (en) Drug composition for blood sugar control
HK1111900A (en) Stabilized ramipril compositions and methods of making
HK1080381A (en) Drug composition for prevention or inhibition of advance of diabetic complication
HK1108359B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1138182

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091104